News | April 04, 2007

The Verdict is Still Out on CAD for Mammo

April 5, 2007 - Controversy over the effectiveness of CAD for screening mammography mounted with recent findings from a study led by Joshua J. Fenton, M.D., M.P.H., on the influence of computer-aided detection (CAD) on the performance of screening mammography, which was published in the April 2007 issue of The New England Journal of Medicine (NEJM). Researchers found that the use of CAD was associated with reduced accuracy of interpretation of screening mammograms.

The study evaluated the association between the use of CAD at mammography facilities and the performance of screening mammography from 1998 through 2003 at 43 facilities in three states. With data collected from 222,135 women and 429,345 mammograms, researchers found that diagnostic specificity decreased from 90.2 percent before implementation to 87.2 percent after implementation, the positive predictive value also decreased from 4.1 percent to 3.2 percent and the rate of biopsy increased by 19.7 percent. Analyses of data from all 43 facilities showed that the use of CAD was associated with significantly lower overall accuracy than was non-use.

In an editorial commentary, published in the same issue of the Journal, Ferris M. Hall, M.D., acknowledged that while the study was �the most comprehensive study analysis of computer-aided detection in breast screening to date,� it was flawed due to the failure to assess the time required to adjust to CAD � the seven sites contributing CAD cases to the Fenton study had been using CAD for a time period ranging from 2 months to several years with an average amount of time in use of 7 months.

Related Content

Lunit Unveiling AI-Based Mammography Solution at RSNA 2018
News | Mammography | November 15, 2018
Medical artificial intelligence (AI) software company Lunit will be returning to the 104th Radiological Society of...
MaxQ AI Receives FDA Clearance for Accipio Ix Intracranial Hemorrhage Platform
Technology | Artificial Intelligence | November 07, 2018
MaxQ AI announced that its Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance...
iCAD Announces Positive Clinical Results for Artificial Intelligence Tomosynthesis Technology
News | Mammography | October 11, 2018
iCAD Inc. announced positive clinical results of its new digital breast tomosynthesis (DBT) cancer detection software,...
SimonMed Deploys ClearRead CT Enterprise Wide
News | Computer-Aided Detection Software | September 17, 2018
September 17, 2018 — National outpatient physician radiology group SimonMed Imaging has selected Riverain Technologie
iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Technology | Breast Density | August 08, 2018
iCAD announced U.S. Food and Drug Administration (FDA) clearance of its latest artificial intelligence (AI) software...
Riverain Technologies Issued U.S. Patent for Vessel Suppression Technology
News | Computed Tomography (CT) | June 14, 2018
Riverain Technologies announced that the United States Patent and Trademark Office (USPTO) has awarded the company a...
FDA Issues Proposed Order to Reclassify Certain Radiological Medical Image Analyzers
News | Computer-Aided Detection Software | June 01, 2018
The U.S. Food and Drug Administration (FDA) is issuing a proposed order to reclassify certain radiological medical...
Median Technologies and the Nice University Hospital to Use AI in Lung Cancer Screening
News | Artificial Intelligence | March 15, 2018
March 15, 2018 – Median Technologies, the industry-leading Imaging Phenomics Company and the Nice University Hospital
FDA Clears First AI-Powered Clinical Decision Support Software for Stroke
Technology | Clinical Decision Support | February 14, 2018
The U.S. Food and Drug Administration (FDA) announced marketing clearance for Viz.AI’s Contact application, the first ...